GBIO
Generation Bio Co.·Healthcare
5.34
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $3.0052W H: $7.52
GBIO NEWS
businesswire.com
Mar 15
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO's proprietary microsphere technology. Under the agreement, Samsung Bioepis will be given a full license right for the novel long-acting semag.
defenseworld.net
Mar 1
Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages
Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has earned an average rating of "Hold" from the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The
